Tactile Systems Launches Next-Gen AffloVest for Respiratory Care

MINNEAPOLIS—Tactile Systems Technology, Inc., a medical technology company providing therapies for people with chronic disorders, announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system. The system is used as a treatment option for chronic neuromuscular and respiratory conditions, including cystic fibrosis and bronchiectasis, across pediatric and geriatric populations. The new generation is introducing enhancements to patient comfort, ease of use and connected care capabilities to support long-term therapy adherence.

“Commercial introduction of the next-generation AffloVest system reflects our ongoing commitment to innovation that improves the lives of patients who depend on our therapies every day, and we are pleased to make our upgraded airway clearance product available ahead of this year’s winter respiratory season,” said Sheri Dodd, CEO of Tactile Medical. “Importantly, the new system preserves the same proven clinical foundation that clinicians trust, while delivering a more comfortable and connected experience, reinforcing AffloVest’s position as a versatile solution for chronic respiratory patients, including those with bronchiectasis, at every stage of life. We designed this new system with the entire care network in mind, from the patient managing their condition to the clinician guiding their care.”

The company said that while medications target inflammation and infection, they do not directly address retained mucus, one of the primary drivers of impaired lung function and disease progression. HFCWO therapy, including AffloVest, mechanically mobilizes and facilitates the removal of mucus secretions to improve ventilation and support overall respiratory health.

The next-generation AffloVest also offers built-in Wi-Fi and Bluetooth connectivity, equipping clinicians with the real-world data needed for more informed, personalized treatment discussions. DME providers also gain access to therapy utilization data that supports patient care and reimbursement requirements with payers.